Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 3Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 17Neoplasms 14Breast Neoplasms 11Melanoma 10Lung Neoplasms 9Multiple Myeloma 8Colorectal Neoplasms 8Prostatic Neoplasms 7Neoplasm Metastasis 7Leukemia, Myeloid, Acute 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Non-Hodgkin 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hodgkin Disease 5Brain Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Squamous Cell Carcinoma of Head and Neck 4Recurrence 4Rectal Neoplasms 4Myelodysplastic Syndromes 4Hematologic Neoplasms 4Glioblastoma 4Endometrial Neoplasms 4Urinary Bladder Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma 3

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphangioleiomyomatosis × 30 days × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡